Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Latest
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more
Sanofi Secures China Rights to RNAi Candidate for Hypertriglyceridemia from Arrowhead
In a major regional licensing agreement, Sanofi has entered into an asset purchase deal with Visirna Therapeutics, a majority-owned subsidiary
Read more
Lilly’s Jaypirca Outperforms Imbruvica in CLL Head-to-Head Phase 3 Trial
Eli Lilly’s Jaypirca (pirtobrutinib), the first and only FDA-approved non-covalent (reversible) BTK inhibitor, has met its primary endpoint in the
Read more
Novartis Gains First-ever Approval for Infant Malaria Medicine
In a breakthrough for pediatric malaria treatment, Novartis has received approval from Swissmedic for Coartem® (artemether-lumefantrine) Baby, marking the first-ever
Read more
FDA Approves Gilead’s Yeztugo® (Lenacapavir) as First Biannual Injectable HIV PrEP
Gilead Sciences, Inc. (Nasdaq: GILD) has announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir) as
Read more
Harbour BioMed and Otsuka to Advance Bispecific T-Cell Engager for Autoimmune Diseases
Harbour BioMed has entered into a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop,
Read more
Sanofi Acquires Blueprint in $9.1B Deal to Bolster Rare Immunological Disease Pipeline
Sanofi has announced a definitive agreement to acquire Blueprint Medicines, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and
Read more
Roche Advances Novel Antibiotic Targeting Superbug into Phase 3 Trials
Swiss pharmaceutical company Roche has announced plans to advance its experimental antibiotic, zosurabalpin, into Phase 3 clinical trials. Developed in
Read more